Welcome to our dedicated page for PHARM news (Ticker: PHARM), a resource for investors and traders seeking the latest updates and insights on PHARM stock.
Pharming Group N.V. (PHARM) is a biotechnology leader developing innovative therapies for rare diseases, including hereditary angioedema (HAE) and activated phosphoinositide 3-kinase delta syndrome (APDS). This page provides investors and healthcare professionals with direct access to the company's latest press releases and official announcements.
Track PHARM's progress through updates on clinical trials, regulatory milestones, and commercialization efforts for therapies like RUCONEST® and Joenja®. Our curated news feed ensures you stay informed about earnings reports, strategic partnerships, and market expansion initiatives without extraneous information.
Discover updates categorized for quick navigation, including product development breakthroughs, financial performance disclosures, and operational strategy refinements. All content is sourced directly from Pharming's verified communications to maintain accuracy and compliance.
Bookmark this page for streamlined access to PHARM's evolving story in rare disease treatment. Check regularly for new developments that demonstrate the company's commitment to addressing unmet medical needs through biopharmaceutical innovation.
Pharming Group (NASDAQ:PHAR) announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference in Boston, USA. CEO Fabrice Chouraqui will deliver a presentation on Tuesday, August 12, 2025, at 12:00 PM EDT/18:00 CEST.
Investors interested in one-on-one meetings with Pharming's management team can arrange them through the company's Investor Relations team or their Canaccord Genuity representative.
Pharming Group (NASDAQ:PHARM) reported strong Q2 2025 financial results with total revenues increasing 26% to US$93.2 million. The growth was driven by RUCONEST® revenue rising 28% to US$80.4 million and Joenja® revenue growing 15% to US$12.8 million.
The company achieved an operating profit of US$10.8 million in Q2 2025, compared to a US$3.1 million loss in Q2 2024. Cash position strengthened to US$130.8 million, up from US$108.9 million in Q1 2025. Based on strong performance, Pharming raised its 2025 revenue guidance to US$335-350 million.
A significant study published in Cell suggests APDS prevalence may be up to 100 times higher than previously estimated, potentially expanding Joenja's addressable market. The company also submitted a new drug application for leniolisib in Japan and launched Joenja® in the UK with first patients on commercial therapy.
Pharming Group (NASDAQ:PHAR) has scheduled its second quarter and first half 2025 financial results announcement and business update for July 31, 2025. The company will host a conference call and webcast for analysts and investors at 13:30 CEST/07:30 EDT on the same day.
Participants interested in asking questions during the event must register for the conference call to receive dial-in information and a unique PIN. A webcast option is also available for those who wish to watch the presentation, with a replay to be made available on Pharming's website after the event.
Pharming Group (NASDAQ:PHAR) announced a webcast to discuss findings from a groundbreaking study published in Cell journal regarding the diagnosis of activated phosphoinositide 3-kinase delta syndrome (APDS). The research, led by Columbia University scientists, successfully identified over 100 new variants with evidence for PI3Kδ pathway hyperactivity.
The study analyzed more than 2,000 PIK3CD/PIK3R1 variants in human T-cell lines, addressing the challenge of variants of uncertain significance (VUS) in APDS diagnosis. Currently, there are over 1,300 known U.S. patients with VUS in PIK3CD and PIK3R1 genes. The findings suggest APDS may be more prevalent than previously estimated.
The webcast featuring Dr. Joshua Milner will take place on June 30, 2025, at 16:30 CEST / 10:30 EDT.
Pharming Group N.V. (Euronext: PHARM/Nasdaq: PHAR) has announced its management's participation in two key investor conferences in June 2025. The company will attend the Jefferies Global Healthcare Conference in New York on June 4-5, where CEO Fabrice Chouraqui will participate in a Fireside Chat Q&A session on June 5 at 2:00 pm EDT/20:00 CEST. Additionally, Pharming will participate in the Portzamparc Mid & Small Caps Conference in Paris on June 18.
Investors can access the Jefferies conference presentation via live webcast and replay through Pharming's website. Those interested in one-on-one meetings with management can arrange them through Pharming's IR team or their Jefferies or Portzamparc representatives.
Pharming Group has announced its 2025 Annual General Meeting (AGM) scheduled for June 11, 2025. The company has nominated Dr. Elaine Sullivan as a new Non-Executive Director for a four-year term, following the departure of Deborah Jorn and Steven Baert.
The AGM agenda includes the reappointment of Jabine van der Meijs and Leonard Kruimer as Non-Executive Directors, and Deloitte Accountants as external auditor. The Board seeks authorization for share issuance and repurchase.
Dr. Sullivan brings extensive pharmaceutical and biotech experience, currently serving on boards of Zealand Pharma and hVIVO. Her background includes senior roles at Eli Lilly and AstraZeneca, plus board positions at IP Group, Evotec AG, and other companies. She holds a PhD in Molecular Virology and BSc in Molecular Biology.
Pharming Group (Euronext: PHARM/Nasdaq: PHAR) has announced multiple presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS) in Philadelphia, scheduled for May 1-4, 2025. The presentations focus on leniolisib, including Phase III clinical data for pediatric patients aged 4-11 years with activated phosphoinositide 3-kinase delta syndrome (APDS).
The presentations include six posters covering various aspects:
- Phase 3 study outcomes of leniolisib in pediatric APDS patients
- Impact of immune dysregulation in Common Variable Immunodeficiency
- APDS-like endotype within common variable immunodeficiency
- Leniolisib's effects in autoimmune lymphoproliferative syndrome
- Demographic characteristics from the APDS-CHOIR registry
- Patient insights on APDS
Note: Leniolisib's effectiveness and safety for pediatric patients aged 4-11 years with APDS has not yet received regulatory approval.
Pharming Group (Euronext: PHARM/Nasdaq: PHAR) has announced it will release its preliminary unaudited first quarter 2025 financial results on Thursday, May 8, 2025. The results will cover the period ended March 31, 2025.
The company will host an analyst and investor presentation at 13:30 CEST/07:30 EDT on the same day. Questions will only be taken from dial-in attendees who register in advance through the provided conference call link.
